Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6288

Project Team

Project lead Celia Mayers

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Eli Lilly (selpercatinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Association for Multiple Endocrine Neoplasia Disorders (AMEND)
  Butterfly Thyroid Cancer Trust
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Welsh Government
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
26 September 2024 - 10 October 2024 Final draft guidance
19 September 2024 This appraisal was considered suitable for streamlined decision making. A subset of the committee (chair and lead team) has reviewed the evidence submitted and the external assessment group (EAG) report, and responses from stakeholders. The chair and lead team consider that this technology can be recommended without the need for a full committee discussion.
05 February 2024 Invitation to participate
05 February 2024 In progress. ITP issued
05 December 2023 - 16 January 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 December 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
05 December 2023 NICE will be undertaking a guidance update for [TA742] Selpercatinib for treating advanced thyroid cancer with RET alterations which recommended the use of Selpercatinib in the Cancer Drugs Fund while further data were collected. The aim of the update is to decide whether or not the drug can be recommended for routine use after data collection is complete. Please see draft timelines we have planned for your information. Following conversations with the company the appraisal is expected to start in approximately early December 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an Invitation to Participate in the appraisal during early February 2024 when we will write to you about how you can get involved.

For further information on our processes and methods, please see our CHTE processes and methods manual